The market for GLP1s — also commonly known as obesity drugs — is projected to exceed $100 bn globally by 2030. Why are these drugs growing in popularity, and could they lead to a paradigm shift in health care? Elif Korkmaz, who covers Health Care Specialist Sales, sits down with Chris Schott, Senior Analyst covering U.S. Diversified Biopharma, and Richard Vosser, Head of European Pharma & Biotech, to discuss the latest developments in this space.



This episode was recorded on Wednesday, November 29th.



This communication is provided for information purposes only. Please read JP Morgan research reports related to its contents for more information including important disclosures.



Copyright 2023 JP Morgan Chase & Co. All rights reserved.